DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0258848A1 Chakravarti Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0258848A1 Chakravarti Et Al US 20090258848A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0258848A1 Chakravarti et al. (43) Pub. Date: Oct. 15, 2009 (54) BIOMARKERS FOR INFLAMMATORY (30) Foreign Application Priority Data BOWEL DISEASE Dec. 6, 2005 (US) ....................... PCT/USO5/44423 (75) Inventors: Shukti Chakravarti, Lutherville, MD (US): Feng Wu, Lutherville, Publication Classification MD (US) (51) Int. Cl. Correspondence Address: A 6LX 3/573 (2006.01) EDWARDS ANGELL PALMER & DODGE LLP C7H 2L/02 (2006.01) P.O. BOX SS874 CI2O I/68 (2006.01) BOSTON, MA 02205 (US) A6IPI/00 (2006.01) (73) Assignee: THE JOHNS HOPKINS (52) U.S. Cl. ............................. 514/177:536/23.1: 435/6 UNIVERSITY, Baltimore, MD (US) (21) Appl. No.: 11/750,114 (57)57 ABSTRACT The present invention relates to methods of determining (22) Filed: May 17, 2007 inflammatory bowel disease status in a subject. The invention O O further relates to kits for determining inflammatory bowel Related U.S. Application Data disease status in a subject. The invention further related to (60) Provisional application No. 60/801,663, filed on May methods of identifying biomarker for determining inflamma 19, 2006. tory bowel disease status in a Subject. Patent Application Publication Oct. 15, 2009 Sheet 1 of 26 US 2009/0258848A1 Patent Application Publication Oct. 15, 2009 Sheet 2 of 26 US 2009/0258848A1 20 10 O - 10 Component1 FIG 2 FIG. FG. 3A 3B FG. 3 Patent Application Publication Oct. 15, 2009 Sheet 3 of 26 US 2009/0258848A1 FIG. 3A Inflammat ion - - - - - - - - - - - - - - - -- - - - - Patent Application Publication Oct. 15, 2009 Sheet 4 of 26 US 2009/0258848A1 FIG. 3B zinc finger protein-like 1 sorting nexin 4 "serine palmitoyitransferase, long chain base subunit 1" stromal cell derived factor receptor 1 acyl-Coenzyme Abinding domain COntaining 3 thioredoxin domain Containing RAN binding protein 2. Cell cycle progression 8 protein K1AA1012 15kDa selenoprotein "At Pase, H+transporting, lysosomal 13kDa, W1 subunit G isoform 1" "protein phosphatase 2, regulatory subunit B (B56),epsilon isoform" K1AA0372 annexin A7 GRP1-binding protein GRSP1 stress-associated endoplasmic reticulum protein 1 TRAF family member-associated NFKB activator "dollohyl-phosphate mannosytransferase polypeptide 1, catalytic subunit" RAN binding protein 2-like 1 "RAP1A, member of RAS oncogene family "rashomologgene family, member E" flucose-1-phosphate guanylytransferase NIMA(never in mitosis genea)-related kinase 7 mitochondrial ribosomal protein L3 ADP-ribosylation factor-like 1 below ear abOve lysosomal-associated protein transmembrane 4 alpha "proteasome (prosome, macropain) subunit, alpha type, 4" "microtubule-associated protein, RP/EB family, member 1" "coatomer protein Complex, subunit beta 2 (beta prime)" pre-B-cell colony enhancing factor 1 activated RNA polymerase II transcription Contactor 4 "methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyclohydrolase" KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 chemokine (C-X-C motif) ligand 3 chemokine (C-X-C motif) ligand 1 chemokine (C-X-C motif) ligand 2 hydroxysteroid (17-beta) dehydrogenase 2 D Component of Complement (adipsin) tripartite motif-containing 3 PTK9L protein tyrosine kinase 9-like (A6-related protein) signal-induced proliferation-associated gene 1 hypothetical protein BC002942 chromosome 22 Open reading frame 3 ataxin 2 related protein mitogen-activated protein kinase kinase kinase 11 "phosphofructokinase, liver" 5-oxoprolinase (ATP-hydrolysing) "ubiquitin-Conjugating enzyme E2M (UBC12 homolog, yeast)" DKFZP566HD73 protein DKFZP586JD619 protein Patent Application Publication Oct. 15, 2009 Sheet 5 of 26 US 2009/0258848A1 CIO Patent Application Publication Oct. 15, 2009 Sheet 6 of 26 US 2009/0258848A1 Patent Application Publication Oct. 15, 2009 Sheet 8 of 26 US 2009/0258848A1 Je-O?) JJb-O? un-O?h un-O? Je-CIO JJB-CIO Un-CIO un-CIO IOIUOO IOIUOO O O O C C Cd cN o d cy o S. N. So Si Se S. S S S S 3 o c d O cs 5 - O O o Cd co CO CO 88WS GS (pun Aeque) CD (un Aeque) CD aneAuossa-Idx 3Abee aneAuoisseIdx eAgee Je-CIO un-CIO IOIUOO v-S 3d 3Co SCo So CS LCO So SO 3O SC So CDO ZEWS LWSW (bun Aeque) CD (pun Aeque) CD aneAuossa.dxc3Apeia L. oneAuossa.Idx 3ApeeN Patent Application Publication Oct. 15, 2009 Sheet 9 of 26 US 2009/0258848A1 pe?oegeGoV pa?oegeundoV7 99||-}NH |QueuoduJOO 09 gueuoduod Patent Application Publication Oct. 15, 2009 Sheet 10 of 26 US 2009/0258848A1 9GLINI@ 19L-INI? ZquêuoduuOO 9 Jueuoduoo Patent Application Publication Oct. 15, 2009 Sheet 11 of 26 US 2009/0258848A1 s c O D s SE O s O C AueeH Au)|eeH g N, so S g S 3 SQ S as2 Sea Sg 3S Oos d c. c. c. c. c. O. O. O. O. O. O. uOSSejdxe 8WS CD 8LVLS CD (pun Aeque) (pun Aue. Ique) oneAuossa-Idxc3A)ee aneAuossa-Idx 3A) ele O t O t D S D S S ? c O (5 O C O s S AueeH AueeH c. oo co rit on C g S N N S S ve O O O O O O O cs O O O uOSSejdxe awS WGTW (un Aeque) (un Aue. Ique) a neAuossa Idx 3Agee aneAuoisseIdx 3Apee Patent Application Publication Oct. 15, 2009 Sheet 12 of 26 US 2009/0258848A1 SE O D S. ? O C AueeH O CN OO V O Y. v c c c O O O O O ITOXO (un Aeque) oneAuossa.dx 3A bay O O O O O O Lo C. L. C. Lo C CN CN vr vas O O LLWO (gun As.IIqb) anea uossa.dx eAgee Patent Appl icat ion Publica tion Oct. 15, 2009 Sheet 15 of 26 US 2009/0258848A1 Patent Application Publication Oct. 15, 2009 Sheet 16 of 26 US 2009/0258848A1 s & & f ( FIG. 11D Patent Application Publication Oct. 15, 2009 Sheet 17 of 26 US 2009/0258848A1 OZ O O 0|- 09 OZ V Zueuoduod Patent Application Publication Oct. 15, 2009 Sheet 18 of 26 US 2009/0258848A1 09 0|| ?ueuoduoOZ 0 O 0|- OZ Eueuoduod Patent Application Publication Oct. 15, 2009 Sheet 19 of 26 US 2009/0258848A1 O CN O O 09 Vr Zueuoduod Patent Application Publication Oct. 15, 2009 Sheet 20 of 26 US 2009/0258848A1 <<<<<<<5555 333333scoupupun-NicoccupN.deseyssagebsbSega's 22 22SSAARAACC2C2C2C2 to SassessessSSSSSZZ 25 IL8, CXCL1, CXCL2, CXCL3, NOS2A, CD REG3A, S100AD, HLA-DRB1, & HLA-DMA, LCN2, BF, DMBT1. UC 18 ADD3, CLDN8, ACBC1. 22 STAT1, STAT3, TAP PSME2, PSMB8, CD PSMB9, PSMB10, IFITM1, IFITM3 CASP 10. 12 WEE1, SPON1, THES1. 26 PECAM1, CD79A, POU2AF1, CCL11, PTODS, TNFFSF7, MMP12, TMP1, IF130, NOTCH3. UC UGDH, PCK1, GGH, CCNT2, CHD1, 63 HNF4G, KLF5, MLLT2, MYB, NR3C2, SATB2, ZNF217, TNPO1, SCAMP1, VPS13A, ATP2B1, SLC16A1, SLC26A2, AQP8, GUCA2A. 3 INF 32 Patent Application Publication Oct. 15, 2009 Sheet 21 of 26 US 2009/0258848A1 © <tcocN Normal CDeff UCaff F.G. 14A FIG. 14B Normal CDef UCaff F.G. 14C FIG. 14D —[ETH -#- Normal CDef UCaff F.G. 14E FIG. 14F Patent Application Publication Oct. 15, 2009 Sheet 22 of 26 US 2009/0258848A1 i i i 25 IL8, CXCL1, CXCL2, CXCL3, NOS2A, REG3A, S100A9, HLA-DRBI, HLA-DMA, LCN2, BF, DMBTI 18 ADD3, CLDN8, ACBC1 > 22 STATI, STAT3, TAPPSME2, PSMB8, PSMB9, PSMC10, IFITM1, IFITM3, CASP10 12 WEEI, SPON1. THESI CCL11, PTODS, TNFRSF7, MMP12, TYMPI, IFI30, NOTCH3 63 UDGH, PCK1, GGH, CCNT2, CHD1, HNF&G, KLF5, MLLT2, MYB, NR3C2, SATB2, ZNF217, TNPO1, SCAMPI, VOS13A, ATP2B1, SLC16A1, SLC26A2, ACP8, GUCAZA FIG. 15 Patent Application Publication Oct. 15, 2009 Sheet 23 of 26 US 2009/0258848A1 O) co Normal CDaff UCaff Normal CDaff UCaff s mm. co Normal CDaff UCaff w Normal CDaff UCaff 0.25 4 0.20 3 N 0.15 S S S 2 a 0.10 S 1 0.05 Co* 0.00 O Normal CDaff UCaff Normal CDaff UCaff FIG. 16 Patent Application Publication Oct. 15, 2009 Sheet 24 of 26 US 2009/0258848A1 FIG. 17C Patent Application Publication Oct. 15, 2009 Sheet 25 of 26 US 2009/0258848A1 Patent Appl ication Publication Oct. 15, 2009 Sheet 26 of 26 US 2009/0258848A1 US 2009/0258848 A1 Oct. 15, 2009 BOMARKERS FOR NFLAMMATORY 0007. The present invention provides a method of quali BOWEL DISEASE fying inflammatory bowel disease status in a subject compris ing measuring at least one biomarker in a sample from the RELATED APPLICATIONS Subject. 0008. In one embodiment, the method of resolution 0001. This application claims priority from U.S. Provi involves Surface-Enhanced Laser Desorption/Ionization sional Application No. 60/633,662, filed Dec. 6, 2004: PCT (“SELDI) mass spectrometry, in which the surface of the Application No.: PCT/US2005/44423 filed Dec. 6, 2005; and mass spectrometry probe comprises adsorbents that bind the U.S. Provisional Application No. 60/801,663, filed May 19, markers. 2006, which are incorporated herein by reference in their 0009. In one aspect, the invention provides biomarkers for entirety. inflammatory bowel disease status comprising one or more of the following Markers 1-97, 99-211, 213-264, 266-401 and combinations thereof. These Markers 1-97, 99-211,213-264, BACKGROUND OF THE INVENTION 266-401 are set forth in Table 1-9, which follows and are sometimes referred to herein as biomarkers of Table I or 0002 Crohn's disease (CD) and ulcerative colitis (UC), similar designations. are complex, heterogeneous, multifactorial diseases involv 0010. In one aspect, the invention provides biomarkers for ing genetic, environmental and microbial factors. These inflammatory bowel disease status comprising one or more of inflammatory bowel disease (IBD) subtypes have distinctive Markers 1-97, 99-211, 213-264, 266-401 and combinations etiopathologies yet share clinical and demographic features. thereof. '" As many as 4 million people worldwide suffer from a form 0011.
Load more

Recommended publications
  • Supplemental Material Table of Contents
    Supplemental material Table of Contents Detailed Materials and Methods ......................................................................................................... 2 Perioperative period ........................................................................................................................... 2 Ethical aspects ................................................................................................................................... 4 Evaluation of heart failure ................................................................................................................. 4 Sample preparation for ANP mRNA expression .................................................................................. 5 Sample preparation for validative qRT-PCR (Postn, Myh7, Gpx3, Tgm2) ............................................ 6 Tissue fibrosis .................................................................................................................................... 7 Ventricular remodeling and histological tissue preservation ................................................................ 8 Evaluation of the histological preservation of cardiac tissue ................................................................ 9 Sample preparation and quantitative label-free proteomics analyses .................................................. 10 Statistical methods ........................................................................................................................... 12 References ........................................................................................................................................
    [Show full text]
  • How Microtubules Control Focal Adhesion Dynamics
    JCB: Review Targeting and transport: How microtubules control focal adhesion dynamics Samantha Stehbens and Torsten Wittmann Department of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA 94143 Directional cell migration requires force generation that of integrin-mediated, nascent adhesions near the cell’s leading relies on the coordinated remodeling of interactions with edge, which either rapidly turn over or connect to the actin cytoskeleton (Parsons et al., 2010). Actomyosin-mediated the extracellular matrix (ECM), which is mediated by pulling forces allow a subset of these nascent FAs to grow integrin-based focal adhesions (FAs). Normal FA turn- and mature, and provide forward traction forces. However, in over requires dynamic microtubules, and three members order for cells to productively move forward, FAs also have to of the diverse group of microtubule plus-end-tracking release and disassemble underneath the cell body and in the proteins are principally involved in mediating micro- rear of the cell. Spatial and temporal control of turnover of tubule interactions with FAs. Microtubules also alter these mature FAs is important, as they provide a counterbalance to forward traction forces, and regulated FA disassembly is the assembly state of FAs by modulating Rho GTPase required for forward translocation of the cell body. An important signaling, and recent evidence suggests that microtubule- question that we are only beginning to understand is how FA mediated clathrin-dependent and -independent endo­ turnover is spatially and temporally regulated to allow cells cytosis regulates FA dynamics. In addition, FA-associated to appropriately respond to extracellular signals, allowing for microtubules may provide a polarized microtubule track for coordinated and productive movement.
    [Show full text]
  • Clinical and Prognostic Significance of MYH11 in Lung Cancer
    ONCOLOGY LETTERS 19: 3899-3906, 2020 Clinical and prognostic significance ofMYH11 in lung cancer MENG-JUN NIE1,2, XIAO-TING PAN1,2, HE-YUN TAO1,2, MENG-JUN XU1,2, SHEN-LIN LIU1, WEI SUN1, JIAN WU1 and XI ZOU1 1Oncology Department, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029; 2No.1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China Received May 14, 2019; Accepted February 21, 2020 DOI: 10.3892/ol.2020.11478 Abstract. Myosin heavy chain 11 (MYH11), encoded by 5-year survival rate is estimated to approximately 18% (2). the MYH11 gene, is a protein that participates in muscle Therefore, novel targets for drug treatment and prognosis of contraction through the hydrolysis of adenosine triphosphate. lung cancer are needed. Although previous studies have demonstrated that MYH11 Myosin heavy chain 11 (MYH11), which is encoded by gene expression levels are downregulated in several types of the MYH11 gene, is a smooth muscle myosin belonging to the cancer, its expression levels have rarely been investigated in myosin heavy chain family (3). MYH11 is a contractile protein lung cancer. The present study aimed to explore the clinical that slides past actin filaments to induce muscle contraction significance and prognostic value of MYH11 expression levels via adenosine triphosphate hydrolysis (4,5). Previous findings in lung cancer and to further study the underlying molecular have shown that in aortic tissue, destruction of MYH11 can mechanisms of the function of this gene. The Oncomine lead to vascular smooth muscle cell loss, disorganization database showed that the MYH11 expression levels were and hyperplasia, which is one of the mechanisms leading to decreased in lung cancer compared with those noted in the thoracic aortic aneurysms and dissections (6,7).
    [Show full text]
  • Communication Pathways in Human Nonmuscle Myosin-2C 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Authors: 25 Krishna Chinthalapudia,B,C,1, Sarah M
    1 Mechanistic Insights into the Active Site and Allosteric 2 Communication Pathways in Human Nonmuscle Myosin-2C 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Authors: 25 Krishna Chinthalapudia,b,c,1, Sarah M. Heisslera,d,1, Matthias Prellera,e, James R. Sellersd,2, and 26 Dietmar J. Mansteina,b,2 27 28 Author Affiliations 29 aInstitute for Biophysical Chemistry, OE4350 Hannover Medical School, 30625 Hannover, 30 Germany. 31 bDivision for Structural Biochemistry, OE8830, Hannover Medical School, 30625 Hannover, 32 Germany. 33 cCell Adhesion Laboratory, Department of Integrative Structural and Computational Biology, The 34 Scripps Research Institute, Jupiter, Florida 33458, USA. 35 dLaboratory of Molecular Physiology, NHLBI, National Institutes of Health, Bethesda, Maryland 36 20892, USA. 37 eCentre for Structural Systems Biology (CSSB), German Electron Synchrotron (DESY), 22607 38 Hamburg, Germany. 39 1K.C. and S.M.H. contributed equally to this work 40 2To whom correspondence may be addressed: E-mail: [email protected] or 41 [email protected] 42 43 1 44 Abstract 45 Despite a generic, highly conserved motor domain, ATP turnover kinetics and their activation by 46 F-actin vary greatly between myosin-2 isoforms. Here, we present a 2.25 Å crystal pre- 47 powerstroke state (ADPVO4) structure of the human nonmuscle myosin-2C motor domain, one 48 of the slowest myosins characterized. In combination with integrated mutagenesis, ensemble- 49 solution kinetics, and molecular dynamics simulation approaches, the structure reveals an 50 allosteric communication pathway that connects the distal end of the motor domain with the 51 active site.
    [Show full text]
  • Catenin Controls Vinculin Binding
    ARTICLE Received 4 Feb 2014 | Accepted 25 Jun 2014 | Published 31 Jul 2014 DOI: 10.1038/ncomms5525 Force-dependent conformational switch of a-catenin controls vinculin binding Mingxi Yao1,*, Wu Qiu2,3,*, Ruchuan Liu2,3, Artem K. Efremov1, Peiwen Cong1,4, Rima Seddiki5, Manon Payre5, Chwee Teck Lim1,6, Benoit Ladoux1,5,Rene´-Marc Me`ge5 & Jie Yan1,3,6,7 Force sensing at cadherin-mediated adhesions is critical for their proper function. a-Catenin, which links cadherins to actomyosin, has a crucial role in this mechanosensing process. It has been hypothesized that force promotes vinculin binding, although this has never been demonstrated. X-ray structure further suggests that a-catenin adopts a stable auto-inhibitory conformation that makes the vinculin-binding site inaccessible. Here, by stretching single a- catenin molecules using magnetic tweezers, we show that the subdomains MI vinculin- binding domain (VBD) to MIII unfold in three characteristic steps: a reversible step at B5pN and two non-equilibrium steps at 10–15 pN. 5 pN unfolding forces trigger vinculin binding to the MI domain in a 1:1 ratio with nanomolar affinity, preventing MI domain refolding after force is released. Our findings demonstrate that physiologically relevant forces reversibly unfurl a- catenin, activating vinculin binding, which then stabilizes a-catenin in its open conformation, transforming force into a sustainable biochemical signal. 1 Mechanobiology Institute, National University of Singapore, Singapore 117411, Singapore. 2 Department of Physics, National University of Singapore, Singapore 117542, Singapore. 3 College of Physics, Chongqing University, No. 55 Daxuecheng South Road, Chongqing 401331, China. 4 Singapore-MIT Alliance for Research and Technology, National University of Singapore, Singapore 117543, Singapore.
    [Show full text]
  • Cardiogenetics Testing Reference Guide December 2018
    Cardiogenetics Testing reference guide December 2018 Why Choose Ambry More than 1 in 200 people have an inherited cardiovascular condition. Ambry’s mission is to provide the most advanced genetic testing information available to help you identity those at-risk and determine the best treatment options. If we know a patient has a disease-causing genetic change, not only does it mean better disease management, it also indicates that we can test others in the family and provide them with potentially life-saving information. Diseases and Testing Options cardiomyopathies arrhythmias Hypertrophic Cardiomyopathy (HCMNext) Catecholaminergic Polymorphic Ventricular Dilated Cardiomyopathy (DCMNext) Tachycardia (CPVTNext) Arrhythmogenic Right Ventricular Long QT Syndrome, Short QT Syndrome, Cardiomyopathy (ARVCNext) Brugada Syndrome (LongQTNext, RhythmNext) Cardiomyopathies (CMNext, CardioNext) Arrhythmias (RhythmNext, CardioNext) other cardio conditions Transthyretin Amyloidosis (TTR) familial hypercholesterolemia Noonan Syndrome (NoonanNext) and lipid disorders Hereditary Hemorrhagic Telangiectasia Familial Hypercholesterolemia (FHNext) (HHTNext) Sitosterolemia (Sitosterolemia Panel) Comprehensive Lipid Menu thoracic aortic aneurysms (CustomNext-Cardio) and dissections Familial Chylomicronemia Syndrome (FCSNext) Thoracic Aneurysms and Dissections, aortopathies (TAADNext) Marfan Syndrome (TAADNext) Ehlers-Danlos Syndrome (TAADNext) Targeted Panels Gene Comparison ALL PANELS HAVE A TURNAROUND TIME OF 2-3 WEEKS arrhythmias CPVTNext CPVTNext CASQ2,
    [Show full text]
  • Microrna Regulatory Pathways in the Control of the Actin–Myosin Cytoskeleton
    cells Review MicroRNA Regulatory Pathways in the Control of the Actin–Myosin Cytoskeleton , , Karen Uray * y , Evelin Major and Beata Lontay * y Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; [email protected] * Correspondence: [email protected] (K.U.); [email protected] (B.L.); Tel.: +36-52-412345 (K.U. & B.L.) The authors contributed equally to the manuscript. y Received: 11 June 2020; Accepted: 7 July 2020; Published: 9 July 2020 Abstract: MicroRNAs (miRNAs) are key modulators of post-transcriptional gene regulation in a plethora of processes, including actin–myosin cytoskeleton dynamics. Recent evidence points to the widespread effects of miRNAs on actin–myosin cytoskeleton dynamics, either directly on the expression of actin and myosin genes or indirectly on the diverse signaling cascades modulating cytoskeletal arrangement. Furthermore, studies from various human models indicate that miRNAs contribute to the development of various human disorders. The potentially huge impact of miRNA-based mechanisms on cytoskeletal elements is just starting to be recognized. In this review, we summarize recent knowledge about the importance of microRNA modulation of the actin–myosin cytoskeleton affecting physiological processes, including cardiovascular function, hematopoiesis, podocyte physiology, and osteogenesis. Keywords: miRNA; actin; myosin; actin–myosin complex; Rho kinase; cancer; smooth muscle; hematopoiesis; stress fiber; gene expression; cardiovascular system; striated muscle; muscle cell differentiation; therapy 1. Introduction Actin–myosin interactions are the primary source of force generation in mammalian cells. Actin forms a cytoskeletal network and the myosin motor proteins pull actin filaments to produce contractile force. All eukaryotic cells contain an actin–myosin network inferring contractile properties to these cells.
    [Show full text]
  • Vinculin Regulates Cell-Surface E-Cadherin Expression by Binding to -Catenin
    Research Article 567 Vinculin regulates cell-surface E-cadherin expression by binding to -catenin Xiao Peng, Laura E. Cuff, Cort D. Lawton and Kris A. DeMali* Department of Biochemistry, University of Iowa Roy J. Carver College of Medicine, Iowa City, IA 52242, USA *Author for correspondence ([email protected]) Accepted 23 November 2009 Journal of Cell Science 123, 567-577 © 2010. Published by The Company of Biologists Ltd doi:10.1242/jcs.056432 Summary Vinculin was identified as a component of adherens junctions 30 years ago, yet its function there remains elusive. Deletion studies are consistent with the idea that vinculin is important for the organization of cell-cell junctions. However, this approach removes vinculin from both cell-matrix and cell-cell adhesions, making it impossible to distinguish its contribution at each site. To define the role of vinculin in cell-cell junctions, we established a powerful short hairpin-RNA-based knockdown/substitution model system that perturbs vinculin preferentially at sites of cell-cell adhesion. When this system was applied to epithelial cells, cell morphology was altered, and cadherin-dependent adhesion was reduced. These defects resulted from impaired E-cadherin cell-surface expression. We have investigated the mechanism for the effects of vinculin and found that the reduced surface E-cadherin expression could be rescued by introduction of vinculin, but not of a vinculin A50I substitution mutant that is defective for -catenin binding. These findings suggest that an interaction between -catenin and vinculin is crucial for stabilizing E-cadherin at the cell surface. This was confirmed by analyzing a -catenin mutant that fails to bind vinculin.
    [Show full text]
  • Phenotypic Variability in Familial Amyloid Polyneuropathy: TTR Modifiers in Caenorhabditis Elegans and D.ICBAS 2019 Human Models
    and Human Human and Caenorhabditis Elegans DOUTORAMENTO CIÊNCIAS BIOMÉDICAS Phenotypic Variability in Familial TTR modifiers Polyneuropathy: Amyloid in Models. FerreiraMiguel Alves D 2019 Miguel Alves Ferreira. Phenotypic Variability in Familial Amyloid Polyneuropathy: TTR modifiers in Caenorhabditis Elegans and D.ICBAS 2019 Human Models. Phenotypic Variability in Familial Amyloid Polyneuropathy: TTR modifiers in Caenorhabditis Elegans and Human Models. Miguel Alves Ferreira INSTITUTO DE CIÊNCIAS BIOMÉDICAS ABEL SALAZAR D 2019 PHENOTYPIC VARIABILITY IN FAMILIAL AMYLOID POLYNEUROPATHY: TTR MODIFIERS IN CAENORHABDITIS ELEGANS AND HUMAN MODELS. Doctoral program in Biomedical Sciences MIGUEL FERNANDO ALVES FERREIRA PHENOTYPIC VARIABILITY IN FAMILIAL AMYLOID POLYNEUROPATHY: TTR MODIFIERS IN CAENORHABDITIS ELEGANS AND HUMAN MODELS. Tese de Candidatura ao grau de Doutor em Ciências Biomédicas submetida ao Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto. Orientador – Prof. Doutora Carolina Luísa Cardoso Lemos Categoria – Professora Auxiliar Convidada Afiliação – Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto. Co-orientadora – Prof. Doutora Alda Maria Botelho Correia de Sousa Categoria – Professora Associada com Agregação Afiliação – Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto. Co-orientadora – Prof. Doutora Sandra Encalada Categoria – Assistant Professor Afiliação – The Scripps Research Institute (TSRI) Porto, 2019 Financial support This study was supported by Fundação
    [Show full text]
  • Hypertrophic Cardiomyopathy- Associated Mutations in Genes That Encode Calcium-Handling Proteins
    Current Molecular Medicine 2012, 12, 507-518 507 Beyond the Cardiac Myofilament: Hypertrophic Cardiomyopathy- Associated Mutations in Genes that Encode Calcium-Handling Proteins A.P. Landstrom and M.J. Ackerman* Departments of Medicine, Pediatrics, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Cardiovascular Diseases and Pediatric Cardiology, and the Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota, USA Abstract: Traditionally regarded as a genetic disease of the cardiac sarcomere, hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease and a significant cause of sudden cardiac death. While the most common etiologies of this phenotypically diverse disease lie in a handful of genes encoding critical contractile myofilament proteins, approximately 50% of patients diagnosed with HCM worldwide do not host sarcomeric gene mutations. Recently, mutations in genes encoding calcium-sensitive and calcium- handling proteins have been implicated in the pathogenesis of HCM. Among these are mutations in TNNC1- encoded cardiac troponin C, PLN-encoded phospholamban, and JPH2-encoded junctophilin 2 which have each been associated with HCM in multiple studies. In addition, mutations in RYR2-encoded ryanodine receptor 2, CASQ2-encoded calsequestrin 2, CALR3-encoded calreticulin 3, and SRI-encoded sorcin have been associated with HCM, although more studies are required to validate initial findings. While a relatively uncommon cause of HCM, mutations in genes that encode calcium-handling proteins represent an emerging genetic subset of HCM. Furthermore, these naturally occurring disease-associated mutations have provided useful molecular tools for uncovering novel mechanisms of disease pathogenesis, increasing our understanding of basic cardiac physiology, and dissecting important structure-function relationships within these proteins.
    [Show full text]
  • Talin-1 Is the Principal Platelet Rap1 Effector of Integrin Activation
    Regular Article PLATELETS AND THROMBOPOIESIS Talin-1 is the principal platelet Rap1 effector of integrin activation 1,2, 3,4, 1, 1 1 1 1 Frederic Lagarrigue, * David S. Paul, * Alexandre R. Gingras, * Andrew J. Valadez, Hao Sun, Jenny Lin, Monica N. Cuevas, Downloaded from http://ashpublications.org/blood/article-pdf/136/10/1180/1756644/bloodbld2020005348.pdf by UNIV OF NC/ACQ SRVCS user on 20 October 2020 Jailal N. Ablack,1 Miguel Alejandro Lopez-Ramirez,1,5 Wolfgang Bergmeier,3,4 and Mark H. Ginsberg1 1Department of Medicine, University of California, San Diego, La Jolla, CA; 2Institut de Pharmacologie et de Biologie Structurale (IPBS), Centre National de la Recherche Scientifique (CNRS), Universite´ Paul Sabatier (UPS), Universite´ de Toulouse, Toulouse, France; 3UNC Blood Research Center and 4Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC; and 5Department of Pharmacology, University of California, San Diego, La Jolla, CA KEY POINTS Ras-related protein 1 (Rap1) is a major convergence point of the platelet-signaling path- ways that result in talin-1 binding to the integrin b cytoplasmic domain and consequent l Blockade of Rap1 binding to talin-1 F0 integrin activation, platelet aggregation, and effective hemostasis. The nature of the and F1 domains connection between Rap1 and talin-1 in integrin activation is an important remaining gap in phenocopies the our understanding of this process. Previous work identified a low-affinity Rap1-binding site defects in integrin in the talin-1 F0 domain that makes a small contribution to integrin activation in platelets. activation observed in platelets lacking We recently identified an additional Rap1-binding site in the talin-1 F1 domain that makes a Rap1a/b.
    [Show full text]
  • Force-Independent Interactions of Talin and Vinculin Govern Integrin-Mediated Mechanotransduction
    bioRxiv preprint doi: https://doi.org/10.1101/629683; this version posted May 7, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Force-independent interactions of talin and vinculin govern integrin-mediated mechanotransduction Paul Atherton1, Franziska Lausecker1, Alexandre Carisey1, Andrew Gilmore1, David Critchley2, Igor Barsukov3, and Christoph Ballestrem1, 1Wellcome Trust Centre for Cell-Matrix Research, University of Manchester, Manchester M13 9PT, UK. 2Department of Biochemistry, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK. 3Institute of Integrative Biology, University of Liverpool, BioSciences Building, Crown Street, Liverpool L69 7ZB, UK. Talin, vinculin and paxillin are core components of the dy- C-terminal D5 tail domain (Vt) that masks the talin binding namic link between integrins and actomyosin. Here we study site in the D1 domain (Cohen et al., 2005). Furthermore, a the mechanisms that mediate their activation and association FRET conformation sensor has shown that vinculin is in an using a mitochondrial-targeting assay, structure-based mutants, open conformation within FAs (Chen et al., 2005). For talin, and advanced microscopy. As expected, full-length vinculin and the primary auto-inhibitory interaction is between the F3 do- talin are auto-inhibited and do not interact with each other in main of the N-terminal FERM domain and R9, one of the this state. Contrary to previous models that propose a critical 13 -helical bundles (R1-R13) in the flexible C-terminal rod role for forces driving talin-vinculin association, our data show a that force-independent relief of auto-inhibition is sufficient to (Calderwood et al., 2013).
    [Show full text]